News Year None2021202020192018 September 8, 2021 Equillium to Present at the H.C. Wainwright 23rd Annual Global Investment Conference August 11, 2021 Equillium Announces Update to EQUALISE Study of Itolizumab in Patients with Systemic Lupus Erythematosus and Lupus Nephritis August 10, 2021 Equillium Reports Second Quarter 2021 Financial Results and Provides Clinical Development Update August 5, 2021 Equillium to Present at the BTIG Virtual Biotechnology Conference July 12, 2021 Equillium Announces Plans to Initiate Phase 3 Pivotal Study of Itolizumab in First-line Treatment of Acute Graft-Versus-Host Disease Following End-of-Phase 1 Meeting with the FDA June 11, 2021 Equillium Announces Positive Topline Results from the EQUATE Study in First-line Treatment of Acute Graft-Versus-Host Disease June 10, 2021 Equillium Presents Data on Target Engagement and Modulation of CD6 on T Cells with Itolizumab at the International Society for Advancement of Cytometry June 9, 2021 Equillium to Present at the JMP Securities Life Sciences Conference June 7, 2021 Equillium to Collaborate with Oxford University and Kennedy Institute of Rheumatology to Investigate Role of the CD6-ALCAM Pathway and Itolizumab in Rheumatic Diseases June 3, 2021 Equillium to Host Conference Call Following Presentation of Data from the EQUATE Study in Acute Graft Versus Host Disease at the EHA2021 Virtual Congress of the European Hematology Association on June 11 Pagination Current page 1 Page 2 Page 3 Next page next › Last page last » Displaying 1 - 10 of 26
September 8, 2021 Equillium to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
August 11, 2021 Equillium Announces Update to EQUALISE Study of Itolizumab in Patients with Systemic Lupus Erythematosus and Lupus Nephritis
August 10, 2021 Equillium Reports Second Quarter 2021 Financial Results and Provides Clinical Development Update
July 12, 2021 Equillium Announces Plans to Initiate Phase 3 Pivotal Study of Itolizumab in First-line Treatment of Acute Graft-Versus-Host Disease Following End-of-Phase 1 Meeting with the FDA
June 11, 2021 Equillium Announces Positive Topline Results from the EQUATE Study in First-line Treatment of Acute Graft-Versus-Host Disease
June 10, 2021 Equillium Presents Data on Target Engagement and Modulation of CD6 on T Cells with Itolizumab at the International Society for Advancement of Cytometry
June 7, 2021 Equillium to Collaborate with Oxford University and Kennedy Institute of Rheumatology to Investigate Role of the CD6-ALCAM Pathway and Itolizumab in Rheumatic Diseases
June 3, 2021 Equillium to Host Conference Call Following Presentation of Data from the EQUATE Study in Acute Graft Versus Host Disease at the EHA2021 Virtual Congress of the European Hematology Association on June 11
